Prescription drug · ANDA
Haloperidol NDC 0378-0257
Haloperidol 1 mg/1 · Tablet · Oral · Mylan Pharmaceuticals Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0378-0257-10 | 00378025710 | 1000 TABLET in 1 BOTTLE, PLASTIC (0378-0257-10)Marketed from Jun 10, 1986 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Haloperidol
- Generic name (nonproprietary)
- haloperidol
- Active ingredients
- Haloperidol — 1 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Mylan Pharmaceuticals Inc.
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 070278
- Marketing start
- Marketing end
- Identifiers
- Product ID 0378-0257_1b33ae94-4fa5-4298-a713-3e049c47588cSPL ID 1b33ae94-4fa5-4298-a713-3e049c47588cSPL set ID c559b0b0-4087-d12a-e718-c18ccb6811e6RxCUI 197754, 310670, 310671, 310672, 314034, 314035UNII J6292F8L3DUPC 0303780351011
- Pharmacologic class
- Typical Antipsychotic
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400378025710followed by a unit qualifier and the quantityPackage 00378-0257-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
INDICATIONS AND USAGE Haloperidol tablets are indicated for use in the management of manifestations of psychotic disorders. Haloperidol tablets are indicated for the control of tics and vocal utterances of Tourette’s Disorder in children and adults. Haloperidol tablets are effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). Haloperidol tablets are also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 070278
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Haloperidol | Haloperidol 1 mg/1 | TabletOral | Mylan Institutional Inc. | 51079-734 |
| Haloperidol | Haloperidol .5 mg/1 | TabletOral | Mylan Institutional Inc. | 51079-733 |
| Haloperidol | Haloperidol 2 mg/1 | TabletOral | Mylan Institutional Inc. | 51079-735 |
| Haloperidol | Haloperidol 5 mg/1 | TabletOral | Mylan Institutional Inc. | 51079-736 |
| Haloperidol | Haloperidol 2 mg/1 | TabletOral | Mylan Pharmaceuticals Inc. | 0378-0214 |
| Haloperidol | Haloperidol .5 mg/1 | TabletOral | Coupler LLC | 67046-1496 |
| Haloperidol | Haloperidol 5 mg/1 | TabletOral | Cardinal Health 107, LLC | 55154-5059 |
| Haloperidol | Haloperidol 5 mg/1 | TabletOral | Mylan Pharmaceuticals Inc. | 0378-0327 |
| Haloperidol | Haloperidol .5 mg/1 | TabletOral | Mylan Pharmaceuticals Inc. | 0378-0351 |